Prostate Cancer Clinical Trials in Detroit

Showing 181-200 of 355 trials

Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients

NCT03180398

This is a pilot study of implement multi-parametric MR imaging for organ delineation and tumor response assessment of prostate cancer patients being treated with radiation therapy.

Prostate Cancer

Henry Ford Health System9 participantsStarted Oct 2017

Detroit, Michigan, United States

COMPLETEDPhase 1/2< 1 mile

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

NCT01485861

This multicenter, international, Phase Ib/II trial consists of three stages: a Phase Ib, open-label stage in which the recommended Phase II dose was determined for ipataseritib administrated in combination with abiraterone and of apitolisib administrated in combination with abiraterone (this phase is no longer active), a Phase II, 3-arm, double-blind, randomized comparison of ipatasertib with abiraterone and prednisone/prednisolone versus placebo with abiraterone and prednisone/prednisolone and a safety single-arm, open-label cohort of ipatasertib 400 mg daily alone or in combination with prednisone/prednisolone or prednisone/prednisolone plus abiraterone.

Prostate Cancer

Genentech, Inc.298 participantsStarted Jan 2012

Scottsdale, Arizona, United States • San Francisco, California, United States • Fort Myers, Florida, United States +56 more locations

Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Prostate Cancer Trials in Other Cities

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination Thru Engagement in Mindfulness Education

Hypofractionated Whole-Pelvis Radiotherapy (WPRT) vs Conventionally-Fractionated WPRT in Prostate Cancer

Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer

PSMA-PET Registry for Recurrent Prostate Cancer

Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

A Study of FT-7051 in Men With MCRPC

Pioneering Advances in Care and Education (PACE)

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer

Other Conditions in Detroit